Evidence map›Paper›PMID 36606100›Full record

Observational studyCanadian journal of gastroenterology & hepatology2022

A Comprehensive Hepatitis B Surface Antigen-Positive Patient-Centered Screening and Linkage to Care Strategies Targeting Microelimination of Hepatitis C Virus Infection in Chongqing, China.

Dachuan Cai, Dazhi Zhang, Peng Hu, Hong Ren

Registry-linked trialOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in Canadian journal of gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03794791 (A Comprehensive HBsAg-positive Patients Centered Screening Strategy Targeting HCV), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03794791 completednot on this map

A Comprehensive HBsAg-positive Patients Centered Screening Strategy Targeting HCV(Hepatitis C) Micro-elimination (CHARSET) in Chongqing, China Establishment of a Model Toward HCV Elimination

Typeobservational_patient_registrySponsorHong RenRan2019 to 2020Enrolled10,000ConditionsHepatitis B and Hepatitis C (Disorder)Armseducation, no education
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dachuan CaiDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.ORCID 0000-0003-3269-8549
Dazhi ZhangDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Peng HuDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hong RenDepartment of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.ORCID 0000-0002-4557-0918
Ministry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The likelihood of coinfection increases in regions where HBV is endemic because of the similar transmission route. China is another endemic nation, with 5.9% of the population being HBsAg-positive. This study aimed to evaluate the prevalence of HCV antibody positivity in HBsAg-positive subjects, HCV RNA positivity in anti-HCV positive subjects, and HBV/HCV coinfection with the hope of exploring hepatitis C microelimination using currently available therapies. Method: 12,500 HBsAg-positive serum samples were collected. All samples were screened for anti-HCV. Furthermore, positive samples were screened for HCV RNA. All patients with positive HCV RNA were followed up for suspicious transmission routes of HCV and linkage to care. Results: 44 out of 10,560 (0.4%) patients with positive HBsAg had detectable anti-HCV. There were 32 males and 12 females, with a statistical difference. 17 out of 44 were HCV RNA positive. Among them, 15 out of 38 patients were HCV RNA positive; 8 patients had started anti-HCV treatment with the DAA regimen, while the other 7 patients had not. After patient education, one patient had begun treatment and reached SVR12, while three patients still refused anti-HCV treatment. Conclusion: The HCV/HBV coinfection prevalence was found to be lower in this study. Even though HBV and HCV share a somewhat similar transmission route, HBsAg-positive subjects may not be at high risk for HCV infection. The process of hepatitis C's microelimination could be accelerated by increasing patient awareness and education. This trail is registered with NCT03794791.

Indexed as

CoinfectionHepatitis BHepatitis CAntiviral AgentsChinaFemaleHepacivirusHepatitis B Surface AntigensHepatitis B virusHepatitis C AntibodiesHumansMalePatient-Centered CareRNA, ViralAntiviral AgentsHepatitis B Surface AntigensHepatitis C AntibodiesRNA, Viral

Identifiers

PMID36606100
PMCPMC9810400
OpenAlexW4312208234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.